Oesophagus and Stomach update dysplasia and early cancer

Similar documents
The Pathologist s Role in the Diagnosis and Management of Neoplasia in Barrett s Oesophagus Cian Muldoon, St. James s Hospital, Dublin

Histopathology of Endoscopic Resection Specimens from Barrett's Esophagus

Greater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy

Barrett s Esophagus: Old Dog, New Tricks

Barrett s Esophagus. Abdul Sami Khan, M.D. Gastroenterologist Aurora Healthcare Burlington, Elkhorn, Lake Geneva, WI

Greater Manchester & Cheshire Guidelines for Pathology Reporting of Oesophageal and Gastric Malignancy

Burning Issues in the Esophagus

Barrett Esophagus - RadioFrequency Ablation (BE-RFA) - Project manual + FAQ

Barrett s Esophagus: Review of Diagnostic Issues and Pre- Neoplastic Lesions

malignant polyp Daily Challenges in Digestive Endoscopy for Endoscopists and Endoscopy Nurses BSGIE Annual Meeting 18/09/2014 Mechelen

Histopathology: gastritis and peptic ulceration

Expert panel observations

Management of Barrett s: From Imaging to Resection

Changes to the diagnosis and management of Barrett s Oesophagus

Management of Barrett s Esophagus. Case Presentation

Earlyoesophagealcancer. dr. Nina Zidar Institute of Pathology Faculty ofmedicine University of Ljubljana Slovenia

American Journal of Gastroenterology. Volumetric Laser Endomicroscopy Detects Subsquamous Barrett s Adenocarcinoma

Barrett s Esophagus: What to Do for No Dysplasia, LGD, and HGD?

Joel A. Ricci, MD SUNY Downstate Medical Center Department of Surgery

History. Prevalence at Endoscopy. Prevalence and Reflux Sx. Prevalence at Endoscopy. Barrett s Esophagus: Controversy and Management

5/2/2018. Low Grade Dysplasia of GI Tract. High Grade Dysplasia of GI Tract. Dysplasia in Gastrointestinal Tract: Practical Pearls and Issues

Ablation for Barrett s Esophagus: Burn or Freeze

Barrett esophagus. Bible class Inselspital

AGA SECTION. Gastroenterology 2016;150:

Barrett s Esophagus: Ablate Everyone?

Small Intestine. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition

Tumours of the Oesophagus & Gastro-Oesophageal Junction Histopathology Reporting Proforma

Upper GIT IV Gastric cancer

SAM PROVIDER TOOLKIT

Faculty Disclosure. Objectives. State of the Art #3: Referrals for Gastroscopy (focus on common esophagus problems) 24/11/2014

Gastric and Oesophageal Neuroendocrine tumours. Dr Tim Bracey, Consultant Pathologist MBChB PhD MRCS FRCPath

Present Day Management of Barrett s Esophagus

Update on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017

References. GI Biopsies. What Should Pathologists Assistants Know About Gastrointestinal Histopathology? James M Crawford, MD, PhD

ACG Clinical Guideline: Diagnosis and Management of Barrett s Esophagus

Gastric Cancer Histopathology Reporting Proforma

Definition of GERD American College of Gastroenterology

New Developments in the Endoscopic Diagnosis and Management of Barrett s Esophagus

RFA and Cyrotherapy for Esophageal Disease

12/7/2011. Pathological mimics of malignancy in the GI tract. Professor Neil A Shepherd President, British Division of the IAP

Volumetric laser endomicroscopy can target neoplasia not detected by conventional endoscopic measures in long segment Barrett s esophagus

Quiz Adenocarcinoma of the distal stomach has been increasing in the last 20 years. a. True b. False

Barrett s esophagus. Barrett s neoplasia treatment trends

Gregory G. Ginsberg, M.D.

Morphologic Criteria of Invasive Colonic Adenocarcinoma on Biopsy Specimens

Colon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition

Pathology in Slovenian CRC screening programme:

COLLECTING CANCER DATA: STOMACH AND ESOPHAGUS

SAMs Guidelines DEVELOPING SELF-ASSESSMENT MODULES TEST QUESTIONS. Ver. #

Update on Colonic Serrated (and Conventional) Adenomatous Polyps

Editorial: Advanced endoscopic therapeutics in Barrett s neoplasia; where are we now and where are we heading?

Handling of Upper GI Cancer Specimens

Part 1. A pragmatic approach to common problems in esophageal biopsy pathology

How to remove BE cancer: EMR or ESD? Expected outcome

Current issues in Barrett s oesophagus and the oesophago-gastric junction

위 ESD 후내시경소견 성균관대학교의과대학내과이준행

Large Colorectal Adenomas An Approach to Pathologic Evaluation

Gastric Polyps. Bible class

Sixteen-year follow-up of Barrett s esophagus, endoscopically treated with argon plasma coagulation

Adenocarcinoma of the distal esophagus is a recognized

Endoscopic Submucosal Dissection ESD

THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 97, No. 1, by Am. Coll. of Gastroenterology ISSN /02/$22.00

Gland ducts and multilayered epithelium in mucosal biopsies from gastroesophageal-junction region are useful in characterizing esophageal location

Pathology of the oesophagus and the stomach. Neil A Shepherd Gloucester, UK. Bristol Pathology 1 st Year Training School, The layers of the GI tract

Gastrooesophageal reflux disease. Jera Jeruc Institute of pathology, Faculty of Medicine, Ljubljana, Slovenia

A215- Urinary bladder cancer tissues

Staging Challenges in Lower GI Cancers. Disclosure of Relevant Financial Relationships. AJCC 8 th edition and CAP protocol updates

National Oesophago-Gastric Cancer Audit New Patient Registration sheet Patients with Oesophageal High Grade Glandular Dysplasia

Learning Objectives:

CLINICAL EFFECTIVENESS

Paris classification (2003) 삼성의료원내과이준행

Common Inflammatory Gastrointestinal Disorders: Endoscopic and Pathologic Correlations

From reflux to esophageal cancer. Josh Boys, MD TCV 2 nd year indentured servant

Pathology in Slovenian CRC screening programme: Organisation and quality assurance. Snježana Frković Grazio and Matej Bračko

Case Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.

Treat Barrett s, Remove the Risk. HALO System

Pathologic Assessment of Invasion in TUR Specimens. A. Lopez-Beltran. T1 (ct1)

CLINICAL GUIDELINE FOR THE MANAGEMENT OF BARRETT S OESOPHAGUS Summary.

Current status of gastric ESD in Korea. Jun Haeng Lee. Department of Medicine Sungkyunkwanuniversity School of Medicie, Seoul, Korea

HISTOLOGY. GIT Block 432 Histology Team. Lecture 1: Alimentary Canal (1) (Esophagus & Stomach) Done by: Ethar Alqarni Reviewed by: Ibrahim Alfuraih

B Barrett neoplasia, early, endoscopic mucosal resection of, in Europe, 297

What Every Pathologist Wants the GI Nurse to Know (and how you can help us help you)

PATHOLOGY GROUP GUIDELINES FOR THE EXAMINATION AND REPORTING OF COLORECTAL CANCER SPECIMENS

How to stage early BE cancer - EUS or endoscopic removal?

Gastric Extremely Well-Diferentiated Intestinal-Type Adenocarcinoma: A Challenging Lesion to Achieve Complete Endoscopic Resection

32 Adenocarcinoma of the oesophagogastric junction

Page 1. Is the Risk This High? Dysplasia in the IBD Patient. Dysplasia in the Non IBD Patient. Increased Risk of CRC in Ulcerative Colitis

Medicare Advantage Medical Policy

Management of pt1 polyps. Maria Pellise

Chromoendoscopy or Narrow Band Imaging with Targeted biopsies Should be the Cancer Surveillance Endoscopy Procedure of Choice in Ulcerative Colitis

THE USE OF SPECIAL STAINS IN THE DIAGNOSIS OF BARRETT ESOPHAGUS AND BARRETT DYSPLASIA: RECOMMENDATIONS FROM THE RODGER C. HAGGITT GASTROINTESTINAL

A218 : Esophagus cancer tissues. (formalin fixed)

Endoscopic Management of Barrett s Esophagus

Primary mucinous adenocarcinoma developing in an ileostomy stoma

Head and Neck Pathology Macroscopy and Dissection Dr Tim Bracey

Barrett s Esophagus: State of the Art Management

Diagnostic Difficulties Encountered Among Colorectal Polyps

How to characterize dysplastic lesions in IBD?

Adenoma and Malignant Colorectal Polyp: Pathological Considerations and Clinical Applications

Gastrointestinal pathology 2018 lecture 2. Dr Heyam Awad FRCPath

Transcription:

Oesophagus and Stomach update dysplasia and early cancer Dr Tim Bracey STR teaching 13/4/16 Please check pathkids.com for previous talks

One of the biggest units in the country (100 major resections per annum. 6 OG surgeons, 1 pathologist!) All biopsies of suspected OG cancers/hg dysplasia from 5 hospitals reviewed with radiology /clinical / endoscopic findings

Local OG workload Dysplasia Dysplasia Last audit (2014-2015) showed 524 cases received from Outside PHNT, almost doubled since 2013, with >10% dysplasia cases for review (more difficult than cancer!)

Types of Barrett s oesophagus Long segment 3cm Short segment Ultra short segment 1cm OGJ

Types of Barrett s oesophagus Long segment 3cm Short segment Ultra short segment Intestinal metaplasia at the cardia. 1cm OGJ

Sharma et al. Gastroenterology 2006 ;131:1392-9.

Definite Barrett s (UK and USA!)

A diagnosis of BE should not require demonstration of goblet cells in mucosal biopsies Am J Gastroenterol 2009; 104:2588-94.

UK Guidelines 2013 Barrett s oesophagus is considered any portion of the normal distal squamous epithelial lining has been replaced by metaplastic columnar epithelium (>1cm) above OGJ No need for intestinal metaplasia. Endoscopic report should include length of Barrett s using the Prague criteria. Short segments of columnar epithelium (<3cm) with no intestinal metaplasia and no native oesophageal structures should be regarded as equivocal for a diagnosis of Barrett s oesophagus. All cases of suspected dysplasia / indefinite for dysplasia should be reviewed by a second pathologist with a specialist GI interest. p53 immunostaining to the histopathological assessment may improve the diagnostic reproducibility of a diagnosis of dysplasia

Only a quarter of LGD is confirmed at specialist center Confirmed cases have 9.1% risk of progression in 3yrs ND and IFD have 0.6% and 0.9% progression rate

Types of dysplasia in Barrett s oesophagus Adenomatous type Gastric foveolar type. Crypt dysplasia. Mixed?Gastric pyloric type Grading of gastric foveolar-type dysplasia in Barrett's esophagus. Mahajan D1, Bennett AE, Liu X, Bena J, Bronner MP. Mod Pathol. 2010 Jan;23(1):1-11. Gastric/fovolar type dysplasia has no requirement for intestinal metaplasia!!

Indefinite for dysplasia PPI increased Repeat biopsy 6/12 No dysplasia

Indefinite for dysplasia Doesn t mean we are indecisive! It is a holding category and the reasons for using it should be stated in the report Favour reactive or suspect dysplasia? Inflammation or technical (eg. Small bx) optimisation of acid suppression and repeat biopsy is recommended

A1 A2 A3 B1 B2 B3

A1 A2 A3 B1 B2 B3 A1 A2 A3 B1 B2 B3 Path 1 o Dys o Dys Indef Indef Indef Indef Path 2 Indef Indef LGD Indef Indef Indef Path 3 LGD LGD LGD LGD LGD Indef Path 4 o Dys o Dys Indef Indef Indef Indef

Sharp cutoff / abrupt transition favours dysplasia

Specific areas of difficulty Small biopsies, poor quality H&Es (IFD,L s) Acute inflammation Juxtaposition of intestinal and gastric type glands Squamo-columnar junction Stromal invasion

Acute inflammation

Juxtaposition of intestinalised and non-intestinalised glands.

Look for surface maturation

Stroma in non-dysplastic Barrett s

Markers in the diagnosis of Barrett s dysplasia Are there any fancy stains that help?

Sporadic adenoma Colitis-associated colon cancer Barrett s

Sporadic adenoma p53 Colitis-associated colon cancer Barrett s

p53 Significant staining pattern Strong staining Absent staining pattern Significant p53 staining in area of interest correlates with likely disease progression Kaye PV et al. Histopathology 2009;54:699-712

This is normal

This is normal

If only it were always this easy (LGD)

If only it were always this easy (LGD + p53)

Remember (complete) loss of p53 expression also correlates with neoplasia

High grade dysplasia Easier to diagnose for the generalist but still some difficulties If there is a nodule then distinction from low grade dysplasia on a bx is academic Even flat HGD now ablated with RFA I am particularly interested in features which reliably predict invasion on a subsequent excision specimen, and particularly those that may predict risk of (LN) metastasis

Name two textbook worthy histological features of invasive adenocarcinoma on a mucosal biopsy

Single cell / signet ring infiltration of lamina propria demonstrated with MNF116 immuno. Older pathologists will tell you mucin stain is best (but they are wrong)

= submucosal invasion (?+arterioles)

But note that dysplastic glands in submucosa doesn t always signify invasion

Do you know any softer histological features that might make you suspicious of invasion in HGD?

* 1. Surface ulceration* * may not be reliable in exophytic lesions

2. Extensive cribriform / solid pattern

3. At least 3 dilated dysplastic tubules per biopsy

4. Extensive neutrophils not useful in my experience

5. Pagetoid infiltration of squamous epithelium strongly predictive of invasion

5. Pagetoid infiltration of squamous epithelium strongly predictive of invasion

CK 5 (brown) & CAM5.2 (red)

CK 5 (brown) & CAM5.2 (red)

High grade dysplasia (suspicious) At least intramucosal adenocarcinoma

EMR (endoscopic mucosal resection

What is the implication of diagnosing submucosal invasion in EMR?

Submucosal (pt1b) invasion predicts LN metastasis

T1a T1a T1b T1b T1a lamina propria. T1b muscularis mucosae. T1c superficial submucosa. T1d deep submucosa. Liu L et al. Am J Surg Pathol. 2005 Aug;29(8):1079-85.

Endoscopic mucosal resection (EMR) Usually diathermy artefact no need to ink. Often multiple with dysplasia at circumferential margins. Orientation and exact site usually lost. Diagnostic, therapeutic and debulking procedure!

Endoscopic mucosal resection (EMR) + Endoscopic submucosal dissection (ESD) Ideally pin out on cork board Fix in >3x volume of formalin

Endoscopic mucosal resection (EMR) 4 15mm Resection not a biopsy. Treat like a cervical cone (do NOT bisect!). If received orientated ink margins.

Endoscopic mucosal resection (EMR) - Ends in one cassette

Ideally only 2 sections a cassette to optimise orientation

Endoscopic mucosal resection (EMR) Diagnosis of dysplasia/imc/ invasive. Stage lesion. Circumferential margins. Deep resection margin. SIMPLE?

Sectioning/fixation artefact

Sectioning/fixation artefact

Sectioning/fixation artefact Where / if possible do not report pt staging and invasion on ends!

Intramucosal adenocarcinoma Poor agreement between histopathologists. Clinicians keen to separate HGD from IMA. Need for criteria for well/moderately differentiated lesions. Consensus - architectural change with horizontal rather than vertical orientation of glands.

Beware dilated bland glands usually (at least) IMA!

Early oesophageal adenocarcinoma often lacks a desmoplastic stroma Pattern of infiltration / low power view important (Cytokeratin).

What staging systems do you know for measuring depth of invasion in early GI cancer?

Oesophagectomy specimens: SM1 upper 1/3 SM2 middle 1/3 SM3 lower 1/3 EMRs Staging of submucosal disease SM1 < 500 um SM2 > 500-1000 um SM3 > 1000 um

pt1a (Shimada 2006) Staging of EMRs M1 Limited to the epithelial layer (HGD / IMC). M2 Invades the lamina propria. M3 Invades into but not through the muscularis mucosa. pt1b (modified Kikuchi) SM1 Infiltrates submucosa <500 microns. SM2 Infiltrates submucosa <1000 microns. SM3 Infiltrates submucosa 1000 microns.

Double muscularis mucosae in 87.5% Barrett s patients!! Takubo et al. Hum Pathol. 1991 Nov;22(11):1158-61.

What immunostains can make our life easier reporting EMRs?

Use of desmin staining in staging EMRs Stage lesion. Measure depth of invasion beyond muscularis mucosae. Desmin staining can be very helpful in delineating the lower border of the muscularis mucosae

Desmin staining

0.8mm 0.8mm invasion beyond muscularis mucosae pt1b, SM2

Simple proforma RCPath dataset pending

MNF116 (brown) & desmin (red) The future?

Simple? This ppt will be on pathkids.com with all the others! Please don t re-publish my slides anywhere online as many of them belong to Marco Novelli at UCH but I have used them with his permission!